U. P. Pharmacy Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 09-07-2024
- Paid Up Capital ₹ 0.50 M
as on 09-07-2024
- Company Age 14 Year, 1 Month
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 1.25 Cr
as on 09-07-2024
- Revenue -14.52%
(FY 2020)
- Profit -67.25%
(FY 2020)
- Ebitda -10.12%
(FY 2020)
- Net Worth 1.00%
(FY 2020)
- Total Assets 3.75%
(FY 2020)
About U. P. Pharmacy
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.50 M.
The company currently has active open charges totaling ₹1.25 Cr.
Aditya Yadav, Naveen Sinha, and Rajeev Chauhan serve as directors at the Company.
- CIN/LLPIN
U24232DL2010PLC210326
- Company No.
210326
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
11 Nov 2010
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
South Delhi, Delhi, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at U. P. Pharmacy?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Aditya Yadav  | Director | 12-Feb-2016 | Current |
| Naveen Sinha | Additional Director | 11-Jun-2020 | Current |
| Rajeev Chauhan | Director | 11-Nov-2010 | Current |
Financial Performance and Corporate Structure Insights of U. P. Pharmacy.
U. P. Pharmacy Limited, for the financial year ended 2020, experienced significant reduction in revenue, with a 14.52% decrease. The company also saw a substantial fall in profitability, with a 67.25% decrease in profit. The company's net worth moved up by a moderate rise of 1%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of U. P. Pharmacy?
In 2020, U. P. Pharmacy had a promoter holding of 99.50% and a public holding of 0.50%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Uttar Pradesh Bio Technology LimitedActive 14 years 3 monthsAditya Yadav and Rajeev Chauhan are mutual person
- Deepshri Infratech Private LimitedActive 1 year 6 months
Naveen Sinha and Rajeev Chauhan are mutual person
- Triveni Autofab Industries Private LimitedActive 15 years 4 months
Rajeev Chauhan is a mutual person
- Rani Developers (Agrotech) India Private LimitedActive 24 years 12 days
Rajeev Chauhan is a mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 22 Feb 2016 | ₹1.25 Cr | Open |
How Many Employees Work at U. P. Pharmacy?
Unlock and access historical data on people associated with U. P. Pharmacy, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of U. P. Pharmacy, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped U. P. Pharmacy's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
